

LE GINECO A L'ESGO 2024 !

BEST ORAL Cervical cancer – Jeudi 7 mars à 13h35

- Patient-Reported Outcomes: **ENGOT-Cx11/GOG 3047/KEYNOTE-A18**
- **BEATcc (ENGOT-CX10/GEICO 68-C/JGOG1084/GOG-3030)**
- **InnovaTV301-ENGOT-cx12**

Mini ORAL Cervical cancer – Vendredi 8 mars à 9h50

- Quality Assurance for Surgery and Pathology: **SENTICOL III**
- Surgical Approach, Preoperative LEEP/Cone Biopsy and Patterns of Recurrence and Death - **CCTG CX.5/SHAPE**

Best 3 minutes presentation – Vendredi 8 mars à 10h55

- Benefit From Atezolizumab in Patients with A Poor Prognostic Ovarian Cancer in First-Line Setting: **IMAGYN-050 Trial**

BEST ORAL Ovarian cancer – Samedi 9 mars à 14h05

- Leuven test HRD - **PAOLA-1/ENGOTov25 Trial**
- BRCA mutation - **ENGOT-ov41-ANITA trial**

Mini ORAL Ovarian cancer – Samedi 9 mars à 15h25

- **AGO-OVAR 2.21** : subgroup analyses

Poster session – Vendredi 8 mars 15h – Exhibition Hall

- De nombreux posters : **GREAT, UTOLA, Paola-1, Neopembrov**

BEST ORAL SESSION – Cervical and ovarian cancer**ENGOT-cx11**
PRO**Sandro Pignata**

Patient-Reported Outcomes from The Phase 3, Randomized, Double-Blind, Placebo-Controlled ENGOT-Cx11/GOG 3047/KEYNOTE-A18 Study of Pembrolizumab Plus Concurrent Chemoradiotherapy in Patients with High-Risk Locally Advanced Cervical Cancer

BEAT-CC**Ana Oaknin**

BEATcc (ENGOT-CX10/GEICO 68-C/JGOG1084/GOG-3030), A Randomized Phase 3 Trial of First-Line Atezolizumab with Bevacizumab and Platinum-Based Chemotherapy for Metastatic (Stage IVB), Persistent or Recurrent Cervical Cancer

ENGOT-cx12
InnovaTV301**Antonio Gonzales**

InnovaTV 301/ENGOT-Cx12/GOG-3057: A Global, Randomized, Open-Label, Phase 3 Study of Tisotumab Vedotin Versus Investigator's Choice of Chemotherapy In 2L or 3L Recurrent or Metastatic Cervical Cancer

PAOLA-1
Test HRD
Leuven**Liselore Loverix**

The Leuven PARPi Benefit Test as Improved Approach for Prediction of PARPi Benefit in the PAOLA-1/ENGOTov25 Trial

ANITA
BRCA mutation**Michel Fabbro**

Impact Of BRCA Mutation Status on Efficacy of Atezolizumab Combined With Platinum-Based Chemotherapy and Maintenance Niraparib for Late-Relapsing Recurrent Ovarian Cancer: Subgroup Analysis of the ENGOT-Ov41/GEICO 69-O/ANITA Phase 3 Trial

MINI ORAL Cervical cancer & Best 3 minutes**SENTICOL III****Fabrice Lécuru**

Quality Assurance For Surgery And Pathology For Patients Randomized Before 2022 In SENTICOL III (International Validation Study Of Sentinel Node Biopsy In Early Cervical Cancer)

SHAPE**Marie Plante**

Surgical Approach, Preoperative LEEP/Cone Biopsy And Patterns Of Recurrence And Death In Low-Risk Cervical Cancer - Analysis Of The International CCTG CX.5/SHAPE Phase III Trial

IMAGYN - 050**Benoît You**

Benefit From Atezolizumab In Patients With A Poor Prognostic Ovarian Cancer In First-Line Setting: IMAGYN-050 Trial